Format

Send to

Choose Destination
Cancer Res. 2011 Jul 1;71(13):4598-607. doi: 10.1158/0008-5472.CAN-11-0320. Epub 2011 May 13.

RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma.

Author information

1
Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga, Japan.

Abstract

RECQL1 and WRN proteins are RecQ DNA helicases that participate in suppression of DNA hyper-recombination and repair. In this study, we report evidence supporting their candidacy as cancer therapeutic targets. In hypopharyngeal carcinomas, which have the worst prognosis among head and neck squamous cell carcinomas (HNSCC) that are rapidly rising in incidence, we found that RECQL1 and WRN proteins are highly expressed and that siRNA-mediated silencing of either gene suppressed carcinoma cell growth in vitro. Similarly, siRNA administration in a murine xenograft model of hypopharyngeal carcinoma markedly inhibited tumor growth. Moreover, combining either siRNA with cis-platinum (II) diammine dichloride significantly augmented the in vivo anticancer effects of this drug that is used commonly in HNSCC treatment. Notably, we observed no recurrence of some tumors following siRNA treatment in this model. Our findings offer a preclinical proof of concept for RECQL1 and WRN proteins as novel therapeutic targets to treat aggressive HNSCC and perhaps other cancers.

PMID:
21571861
DOI:
10.1158/0008-5472.CAN-11-0320
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center